Pharmaceutical Glass Vials and Ampoules Market Size, Share & Trends Analysis Report By Applications (Vaccines, Others (Insulin, Biopharma, etc.)) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Pharmaceutical Glass Vials and Ampoules Market Size

The global pharmaceutical glass vials and ampoules market size was valued at USD 15.77 billion in 2025 and is projected to grow from USD 16.77 billion in 2026 to USD 27.47 billion by 2034, registering a CAGR of 6.36% during the forecast period from 2026 to 2034. Europe dominated the pharmaceutical glass vials and ampoules market with a market share of 34.6% in 2025.

The two most extensive subcategories of parenteral packaging are vials and ampoules. The pharmaceutical sector mainly uses vials and ampoules. In the pharmaceutical business, they are widely used to fill and store a variety of medications and drugs. These items can be used to store a variety of medications, chemicals, and other substances that are chemically unstable. They aid in avoiding contamination of the medicines and other items kept nearby.

Segmental Analysis

Based on Application

The vaccines segment owns the highest market share and is expected to grow at a CAGR of 10.3% during the forecast period. As COVID-19 spreads globally at various phases, vaccinations have become imperative. The preferred container in use today and in the past is borosilicate glass, utilized more frequently by all vaccine makers worldwide. The glass composition is listed as follows by the US National Institute of Standard and Technology: 80.8% silicon dioxide, 12.56% boron oxide, 3.98% sodium oxide, and 2.28% aluminum oxide (Al2O3) make up the compound. The boron oxide component stabilizes and maintains the vaccine's pH in an unaltered state.

With 20 manufacturing facilities across the globe, Schott AG is one of the market's pioneers in developing borosilicate vials and can produce containers for more than 1 billion doses of the COVID-19 vaccine. Furthermore, according to Wion, Schott AG provides the vials needed to preserve the vaccine for 75% of the vaccination programs. Additionally, Schott provided containers for two billion vaccine doses in June 2020 for several top pharmaceutical firms that produce Covaxin, including AstraZeneca, Pfizer/BioNTech, Janssen, and Moderna. Additionally, vendors provide filling options for ampoules and vials, making packaging for vaccine producers simple. For instance, the Stevanato Group provided a pharmaceutical company in India with a Coombi machine for liquid ampoules and lyophilized vials so that controls for two different primary containers filled with two different drugs could be set up on the same machine.

Request Customizationto receive a tailored report.

Gene therapy, insulin storage, and APIs are just a few other applications for glass vials and ampoules. For many years, injectable medications have been packaged in glass ampoules, and this trend is projected to continue during the forecast period. They are also utilized in pharmaceutical and chemical laboratories to preserve and store pharmaceutical fluids, capsules, and liquids. Glass ampoules have significantly impacted product shelf life since they prevent pharmaceutical contamination and mixing. Additionally, with more people worldwide developing rheumatoid arthritis, the use of anti-rheumatic medicines is increasing. Many anti-rheumatic medications, including methotrexate, Actemra, and Orencia, are available in vials, which is anticipated to drive the global pharmaceutical glass vials and ampoules market.

Speak to an Analystto discuss market opportunities.

Regional Analysis

Europe Dominates the Global Market

Europe is the most significant shareholder in the global pharmaceutical glass vials and ampoules market and is expected to grow at a CAGR of 6.4% during the forecast period. Schott AG and Gerresheimer AG are two of the world's most renowned pharmaceutical glass packaging businesses. These businesses steadily grow their national presence by introducing new products and increasing their capacity. For instance, Aenova Holding GMBH provides packaging services for vials, ampoules, and syringes. It can make 120 million syringes, 250 million ampoules, and 70 million vials annually. Following the installation of high-speed filling lines in many domestic pharmaceutical companies, glass ampoules are anticipated to produce greater yields. To hasten the production of vaccinations, these pharmaceutical firms collaborate with suppliers of aseptic filling equipment. For instance, a pharmaceutical business acting as a CDMO joined Steriline in February 2021. One of the biologics industries with the highest growth is gene therapy. It has a limited patient base, which increases the need for pre-sterilized vials and the validation of medications. Due to the actual drug usage, advancements in medical knowledge, and rising prevalence of diseases in the UK, the pharmaceutical business is one of the country's most important sectors of the economy. The development of the research-based pharmaceutical sector is also essential to reviving the UK's economy and ensuring its competitiveness in the following years.

Unlock Regional Insightsto access country-level data, & regional trends.

North America is expected to grow at a CAGR of 6.6%, generating USD 5.60 billion during the forecast period. Due to the dominance of the US region in the North American market for pharmaceutical vials and ampoules, major international companies like Schott, Stevanato, Corning, and Gerresheimer are also present. The demand for vials and ampoules has increased steadily along with pharmacological complexity and the prevalence of ailments like diabetes. The US drug agency permitted several businesses to increase COVID-19 vaccine production with larger vials. Additionally, the US Food and Drug Administration (FDA) increased the number of doses extracted from the current vials from the previously allowed 10 to a maximum of 11.

In Canada, numerous companies provide vaccines for diseases like influenza, polio, diphtheria, and tetanus. It would be difficult to quickly retool these facilities to combat COVID-19 and create COVID-19 vaccines. For instance, the Connaught Campus in Toronto is run by Sanofi Pasteur in Canada, which manufactures vaccines against diphtheria and tetanus. Sanofi spent about CAD 925 million building a new vaccine manufacturing facility at its current location in Toronto. This will increase the supply of the company's FLUZONE high-dose quadrivalent influenza vaccine in Canada by adding antigen and filler capacity.

Asia-Pacific is anticipated to grow significantly during the forecast period. The Indian Express reports that almost 50% of all vaccine vials come from China. One of the biggest producers of vaccine vials worldwide, the region saw increased demand for vaccination vials due to the release of COVID-19 vaccines. As a result, China has taken several actions to meet the demand for vials. In response to the COVID-19 vaccination rush, many businesses in the area have been concentrating on growing their production capacities. The annual manufacturing capacities of some companies have reached tens of billions of units. The manufacturing of other items has been decreased at Sinopharm and Sinovac Biotech to prioritize the production of vaccination vials.

Like this, Chongqing Zhengchuan Pharmaceutical Packaging enlarged its facility in January 2021 by putting in more than 800 manufacturing units, each capable of producing 3 billion neutral and low borosilicate glass goods. Japan, which continuously focuses on creating proprietary treatments, vaccines, and generic medications, has one of the pharmaceutical industries expanding the fastest after the United States. The Japanese government is also promoting this expansion by removing barriers to foreign businesses investing in the area. Piramida, a producer of glass vials and ampoules in Croatia, was acquired by Nipro. Piramida is vital to Japan, particularly in the wake of the COVID-19 pandemic and the increased manufacturing of vaccines. One of the top five producers of glass ampoules for the pharmaceutical sector in Europe is Piramida.

With the number of manufacturing units expected to treble by 2021, the United Arab Emirates stated its plans to establish itself as the global hub for numerous major pharmaceutical corporations. The country's healthcare industry may be further improved by favorable government laws, which are also anticipated to fuel demand for the pharmaceutical glass vials and ampoules market. For instance, a memorandum of understanding (MoU) for the growth of the healthcare and pharmaceutical sector in the nation was signed by the UAE Ministry of Health and Prevention and Jafza, a DP World firm. In a joint venture with the technology firm Group 42, the Chinese government opened a new facility in Abu Dhabi. The factory is being constructed in the Khalifa Industrial Zone with a 200 million dosage annual manufacturing capacity. Three filling lines and five automated packaging lines will be installed, projected to enhance demand for vials in the Middle East and Latin American regions.

List of Key and Emerging Players in Pharmaceutical Glass Vials and Ampoules Market